ReviewMolecular biology reports2025
Berberine and its impact on breast cancer: unveiling key signalling pathways.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Berberine shows potential in mitigating PMApoptosis : an international journal on programmed cell death · 2026Article
- Cellular and Molecular Mechanisms of Berberine in Cancer Therapy: Recent Advances.Archiv der Pharmazie · 2026Review
- Animal- and Plant-Derived Protein Nanocarriers for the Delivery of Natural Compounds in Breast Cancer Chemoprevention.Molecules (Basel, Switzerland) · 2026Review
- Berberine in breast cancer, a multi-targeted therapeutic agent from mechanisms to clinical translation.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Berberine, an isoquinoline derived alkaloid and phytochemical, isolated from barberry and other trees has been known for its medicinal value in Chinese and Indian folk medicine since ages. This short review sheds light on the present-day information on the activity of berberine in ameliorating breast cancer, by evaluation of the mechanisms involved at the cellular and molecular level. Its ability to interact with key receptors and effector proteins as well its role in modulating signalling pathways involving PI3K/AKT/mTOR, MAPK/ERK, NF-ƙB, METTL3/FGF7 regulation, NLRP3 inflammasome and estrogen receptors have been discussed. Its efficacy in inducing apoptosis, arresting cell cycle, halting angiogenesis, cell proliferation and metastasis and reducing inflammation have been explored according to most recent understandings. The need for this review arises from the increasing interest in natural compounds with potential therapeutic applications, especially in breast cancer treatment which remains one of the most prevalent and challenging diseases globally, necessitating exploration of alternative and complementary treatment strategies. This review not only compiles the majority of the reported findings to date on the molecular mechanisms underlying berberine's anti-breast cancer effects but also explores its synergistic potential with various conventional anti-breast cancer drugs. Additionally, it discusses the limitations that restrict berberine's therapeutic application and examines strategies employed to enhance its efficacy. The study is aimed at bridging traditional medicinal knowledge with modern scientific advancements, fostering a deeper understanding of berberine's promise in breast cancer therapy.
Indexed as
Identifiers
40668488What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.